Why Cardio Diagnostics Holdings Stock Is Blasting Higher
Portfolio Pulse from Erica Kollmann
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) announced that its AI-driven molecular heart disease test has received an Innovation Technology contract from Vizient, Inc. This contract will accelerate access to Cardio Diagnostics' novel heart disease tests. Following the announcement, CDIO shares traded higher with more than 103 million shares traded in the session, compared to the stock's 100-day average of less than 704 thousand shares.
October 31, 2023 | 4:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardio Diagnostics' contract with Vizient for its AI-driven heart disease test has led to a surge in its stock trading volume and price.
The news of Cardio Diagnostics' contract with Vizient for its AI-driven heart disease test is directly related to the company and its operations. This contract is likely to increase the company's revenues and market reach, which has led to increased investor confidence and a surge in the stock's trading volume and price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100